MxA and CRP-Guided Use of Antimicrobial Agents for AECOPD

Launched by CAPITAL MEDICAL UNIVERSITY · Jan 11, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "MxA and CRP-Guided Use of Antimicrobial Agents for AECOPD," is designed to explore how well certain blood tests, specifically Myxovirus Resistance A (MxA) and C-Reactive Protein (CRP), can help doctors decide when to use antibiotics for patients experiencing acute flare-ups of chronic obstructive pulmonary disease (AECOPD). The goal is to see if this guided approach can improve patient outcomes compared to standard care.

To participate in this trial, individuals must be at least 40 years old, have a history of smoking, and be diagnosed with mild to severe COPD. They should be currently experiencing a mild to moderate exacerbation of their condition. However, those who require immediate hospitalization or have certain other health issues, like active infections or recent surgeries, will not be eligible. If you join the trial, you can expect to receive either the standard treatment or one guided by the test results, with the hope of finding a better way to manage these flare-ups. This trial is not yet recruiting, so there will be more information available in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥40 years old；
• • Current or former smoker with a minimum smoking history of 10 pack years, clinical diagnosed with mild-to-severe COPD;
• • Presenting with an acute exacerbation of COPD
• • The severity of AECOPD is mild to moderate.
• Exclusion Criteria:
• • Required urgent hospitalization
• • Received interferon therapy within 30 days before screening
• • Had an active systemic inflammatory condition within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery
• • Received vaccine in the past 30 days
• • Active tuberculosis
• • Immunocompromised
• • Presenting with current respiratory failure
• • Clinical suspicion of pneumonia or pulmonary edema.
• • Coexisting bronchiectasis, cystic fibrosis, or asthma
• • Had a concurrent infection at another site, such as urinary tract infections or sinusitis;
• • Contraindications to antibiotics and/or antivirals
• • Known etiology of the present exacerbation
• • Pre-treatment with corticosteroids (cumulative dose of methylprednisolone ≥ 80 mg or equivalent dose) for the present exacerbation.